TV-116

Nov
19

Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape

Breast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases.HER2-positive (+)BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course of treatment. […]

Read More
By Simone Kahmeyer |
DETAIL